PB1890: TRIAL IN PROGRESS: A PHASE II STUDY OF MIDOSTAURIN COMBINED WITH INDUCTION/CONSOLIDATION CHEMOTHERAPY AND AS SINGLE-AGENT MAINTENANCE IN PEDIATRIC PATENTS WITH FLT3-MUTATED ACUTE MYELOID LEUKEMIA

• Dirk Reinhardt,
• Michel Zwaan,
• Dhrubajyoti Pathak,
• Dawid Sawicki,
• Lisa Burgmeyer,
• Muriel Orphee Yokam Tateu,
• Franco Locatelli

Affiliations

Dirk Reinhardt

1 Universitäts-Klinikum, Essen, Germany

Michel Zwaan

2 Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands & Pediatric Oncology, Erasmus MC-Sophia Children’s Hospital, Rotterdam, The Netherlands

Dhrubajyoti Pathak

4 Novartis Pharma AG, Basel, Switzerland

Dawid Sawicki

5 Novartis Ireland Limited, Dublin, Ireland

Lisa Burgmeyer

6 Novartis Pharmaceuticals Corporation, New Jersey, United States

Muriel Orphee Yokam Tateu

7 Novartis Pharma S.A.S., Paris, France

Franco Locatelli

8 IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the sacred Heart, Rome, Italy